SCHEMBL14019031

SCHEMBL14019031

CC(C)(C)c1c(F)c(F)nc(F)c1F

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6970069 0.85 MEN1 (0.32) MEN1MAPTHTTKMT2A
SCHEMBL17998022 0.77
SCHEMBL10212111 0.77
SCHEMBL73292 0.74
SCHEMBL1437045 0.73 MEN1 (0.39) MEN1MAPTHTTKMT2A
SCHEMBL9951972 0.69 MEN1 (0.31) MEN1MAPTHTTKMT2A
SCHEMBL20034064 0.67
SCHEMBL12112190 0.67 MEN1 (0.31) MEN1MAPTHTTKMT2A
SCHEMBL13990717 0.67
SCHEMBL13617319 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11158810-B2 Polycyclic compound and organic light emitting device comprising same LG CHEM, LTD. 2021-10-26 US disclosed
US-20200127207-A1 POLYCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME LG CHEM, LTD. (KR) 2020-04-23 US disclosed
US-20170204134-A1 Cyclising Peptides THE UNIVERSITY OF DURHAM (GB) 2017-07-20 US disclosed
US-7432379-B2 Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists ELAN PHARMACEUTICALS, INC. (US) 2008-10-07 US disclosed
US-7417152-B2 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases ELAN PHARMACEUTICALS, INC. (US) 2008-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11158810-B2 Polycyclic compound and organic light emitting device comprising same CRY1, CYP1A1, CYP1B1 MEN1 190/4885MAPT 1695/4885HTT 3869/4885
US-20200127207-A1 POLYCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME CRY1, CYP1A1, CYP1B1 MEN1 190/4885MAPT 1695/4885HTT 3869/4885
US-20170204134-A1 Cyclising Peptides VIP, NGLY1, NPPA MEN1 151/4885MAPT 4290/4885HTT 1131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.